NCT00391846

Evaluation of Heart Failure Treatment Guided by N-terminal Pro B-type Natriuretic Peptide (NTproBNP) vs Clinical Symptoms and Signs Alone

A Randomised, Single Blind, Multicentre, 9-month, Phase IV Study, Comparing Treatment Guided by Clinical Symptoms and Signs and NT-proBNP vs Treatment Guided by Clinical Symptoms and Signs Alone, in Patients With Heart Failure (HF) and Left Ventricular Systolic Dysfunction

• Status: Completed
• Phase: Phase 4
• Study type: Interventional
• Enrollment: 252 (actual)
• Sponsor: AstraZeneca · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

The purpose is to study if HF treatment guided by NTproBNP in addition to clinical symptoms and signs is more effective than treatment guided by clinical symptoms and signs alone in patients with HF and left ventricular systolic dysfunction

Conditions

• Heart Failure
• Ventricular Dysfunction, Left

Interventions

Type	Name	Description
DRUG	Captopril
DRUG	Enalapril
DRUG	Lisinopril
DRUG	Ramipril
DRUG	Trandolapril
DRUG	Bisoprolol
DRUG	Carvedilol
DRUG	Metoprolol succinate
DRUG	Candesartan
DRUG	Valsartan
DRUG	Eplerenone
DRUG	Spironolactone
DRUG	Diuretics
DRUG	HF treatment according to Swedish guidelines
PROCEDURE	Blood samples
PROCEDURE	The Kansas City Cardiomyopathy Questionnaire (KCCQ)

Timeline

• Start date: 2006-10-01
• Primary completion: 2009-01-01
• Completion: 2009-01-01
• First posted: 2006-10-25
• Last updated: 2012-06-25
• Results posted: 2012-06-18

Locations

39 sites across 1 country: Sweden